- Home
- NNNN vs PK Comparison
NNNN vs PK Comparison
Compare NNNN & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNNN
- PK
- Stock Information
- Founded
- NNNN 2021
- PK 1946
- Country
- NNNN Germany
- PK United States
- Employees
- NNNN N/A
- PK N/A
- Industry
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PK Real Estate Investment Trusts
- Sector
- NNNN Health Care
- PK Real Estate
- Exchange
- NNNN Nasdaq
- PK Nasdaq
- Market Cap
- NNNN 2.2B
- PK 2.1B
- IPO Year
- NNNN 2025
- PK N/A
- Fundamental
- Price
- NNNN $42.80
- PK $10.26
- Analyst Decision
- NNNN
- PK Hold
- Analyst Count
- NNNN 0
- PK 11
- Target Price
- NNNN N/A
- PK $12.85
- AVG Volume (30 Days)
- NNNN 147.4K
- PK 3.5M
- Earning Date
- NNNN 01-01-0001
- PK 07-31-2025
- Dividend Yield
- NNNN N/A
- PK 13.67%
- EPS Growth
- NNNN N/A
- PK N/A
- EPS
- NNNN 0.06
- PK 0.28
- Revenue
- NNNN $8,185,146.00
- PK $2,588,000,000.00
- Revenue This Year
- NNNN N/A
- PK $2.07
- Revenue Next Year
- NNNN N/A
- PK $2.55
- P/E Ratio
- NNNN $776.89
- PK $36.75
- Revenue Growth
- NNNN 21.95
- PK N/A
- 52 Week Low
- NNNN $5.18
- PK $8.27
- 52 Week High
- NNNN $55.65
- PK $16.23
- Technical
- Relative Strength Index (RSI)
- NNNN N/A
- PK 38.51
- Support Level
- NNNN N/A
- PK $11.08
- Resistance Level
- NNNN N/A
- PK $11.31
- Average True Range (ATR)
- NNNN 0.00
- PK 0.34
- MACD
- NNNN 0.00
- PK -0.09
- Stochastic Oscillator
- NNNN 0.00
- PK 18.40
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.